SCHEMBL18486287

SCHEMBL18486287

O=C(O)c1cccc(-c2ncnc3nc[nH]c23)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP2A P11388 2/20 0.62
AKT2 P31751 5/20 0.57
NT5C2 P49902 2/20 0.57
NT5E P21589 1/20 0.57
PRKACA P17612 2/20 0.56
PRKACG P22612 2/20 0.56
PRKACB P22694 2/20 0.56
NEK2 P51955 2/20 0.56
BRD4 O60885 2/20 0.51
ROCK2 O75116 1/20 0.51
LIMK1 P53667 1/20 0.51
BRAF P15056 1/20 0.50
NPC1 O15118 1/20 0.48
ALDH1A1 P00352 1/20 0.48
LMNA P02545 1/20 0.48
CYP1A2 P05177 1/20 0.48
HPGD P15428 1/20 0.48
HTT P42858 1/20 0.48
RAB9A P51151 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29761016 0.82 TOP2A (0.54) TOP2ANT5C2NT5EBRD4ROCK2
SCHEMBL2938675 0.80 AKT2 (0.70) AKT2NT5C2PRKACAPRKACGPRKACB
SCHEMBL18486258 0.80 AKT2 (0.70) AKT2NT5C2NT5EPRKACAPRKACG
SCHEMBL18486378 0.78 TOP2A (0.49) TOP2ANT5C2NT5ELIMK1MAPK1
SCHEMBL4939153 0.74 LMNA (0.69) TOP2ANT5C2NT5EPRKACABRD4
SCHEMBL28424527 0.73 BRD4 (0.49) TOP2AAKT2NT5C2NT5EPRKACA
SCHEMBL29761047 0.71 MTOR (0.51) AKT2BRD4BRAF
SCHEMBL30890069 0.70 MAP2K4 (0.42) TOP2ANPC1ALDH1A1LMNAHPGD
SCHEMBL28753405 0.70 AKT2 (0.60) AKT2PRKACAPRKACGPRKACBNEK2
SCHEMBL1759307 0.70 KMO (0.53) NPC1ALDH1A1HPGDRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3130597-B1 OLIGONUCLEOTIDE HAVING A NON-NATURAL NUCLEOTIDE AT THE 5'-TERMINAL KYOWA KIRIN CO LTD (JP) 2021-11-10 EP disclosed
US-10342819-B2 Oligonucleotide having non-natural nucleotide at 5′-terminal thereof KYOWA HAKKO KIRIN CO., LTD. (JP) 2019-07-09 US disclosed
US-20170354673-A1 OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF KYOWA HAKKO KIRIN CO., LTD. (JP) 2017-12-14 US disclosed
EP-3130597-A1 OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF Kyowa Hakko Kirin Co., Ltd. (JP) 2017-02-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10342819-B2 Oligonucleotide having non-natural nucleotide at 5′-terminal thereof RNGTT, UPF1, NSUN3 TOP2A 409/4885AKT2 3555/4885NT5C2 26/4885
US-20170354673-A1 OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF RNGTT, UPF1, NSUN3 TOP2A 438/4885AKT2 3611/4885NT5C2 26/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.